References
- Maakaron JE, Taher AT. Complications and management of thalassemia intermedia. J Appl Hematol. 2012;3(4):143–146
- Musallam KM, Cappellini MD, Taher AT. Iron overload in β-thalassemia intermedia: An emerging concern. Curr Opin Hematol. 2013;20(3):187–192
- Musallam KM, Taher AT, Rachmilewitz EA. β-Thalassemia intermedia: A clinical perspective. Cold Spring Harb Perspect Med. 2012;2(7):a013482. doi: 10.1101/cshperspect.a013482
- Taher AT, Musallam KM, Cappellini MD, Weatherall DJ. Optimal management of β thalassaemia intermedia. Br J Haematol. 2011;152(5):512–523
- Taher A, Musallam KM, El Rassi F, et al. Levels of non transferrin bound iron as an index of iron overload in patients with thalassaemia intermedia. Br J Haematol. 2009;146(5):569–572
- Taher A, Hershko C, Cappellini MD. Iron overload in thalassaemia intermedia: Reassessment of iron chelation strategies. Br J Haematol. 2009;147(5):634–640
- Taher AT, Porter J, Viprakasit V, et al. Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. Blood. 2012;120(5):970–977
- Taher AT, Musallam KM, Karimi M, et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: The OPTIMAL CARE study. Blood. 2010;115(10):1886–1892
- Kwiatkowski JL. Real-world use of iron chelators. Hematology Am Soc Hematol Edu Program. 2011;2011:451–458
- Taher AT, Musallam KM, Karimi M, et al. Contemporary approaches to treatment of β-thalassemia intermedia. Blood Rev. 2012;26(1):S24–S27
- Maakaron J, Cappellini M, Taher A. An update on thalassemia intermedia. J Med Liban. 2013;61(3):175–182